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Abstract 24 
VEGFA is one of the most potent known inducers of angiogenesis. However, the function of 25 
angiogenic factors in the canine corpus luteum (CL) of pregnancy and in the pregnant uterus and 26 
placenta has not yet been elucidated. Therefore, here we investigated the expression and 27 
localization of VEGFA and its receptors (VEGFR1/FLT1 and VEGFR2/FLK1/KDR) in the 28 
canine CL and utero-placental compartments (ut-pl) throughout pregnancy until prepartum 29 
luteolysis. Antigestagen-mediated effects on expression of VEGF system in ut-pl were elucidated 30 
in mid-pregnant dogs. While displaying high individual variation, the luteal VEGFA was 31 
elevated during pre-implantation and post-implantation, followed by a decrease during mid-32 
gestation, which was more pronounced at the mRNA level, and showed constant expression 33 
afterwards. Within the uterus, it increased following implantation and during mid-gestation in ut-34 
pl compartments, but was downregulated at prepartum luteolysis. Luteal VEGFR1 expression 35 
resembled that of VEGFA; VEGFR2 remained unaffected throughout pregnancy. In ut-pl 36 
compartments, both receptors increased gradually towards mid-gestation; a prepartum decrease 37 
was observed for VEGFR1. Antigestagen-treatment resulted in decreased expression of ut-pl 38 
VEGFR1. In the CL, VEGFA stained in luteal cells. Uterine signals of VEGFA and its two 39 
receptors were observed in epithelial and vascular compartments, and in myometrium. In 40 
placental labyrinth, additionally, trophoblast stained positively. Luteal VEGFR1 was localized to 41 
the luteal cells and tunica media of blood vessels, whereas VEGFR2 stained only in capillary 42 
endothelial cells. The upregulation of luteal and the ut-pl VEGF system during early gestational 43 
stages supports the increased vascularization rate during this time. The diminishing effects of the 44 
prepartum endocrine milieu on VEGFA function seem to be more pronounced in the ut-pl units. 45 
Key words: domestic dog, corpus luteum (CL), uterus-placenta complex (ut-pl), angiogenesis, 46 
vascular endothelial factor (VEGF) system 47 
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1 Introduction 48 
In the reproductive tract, angiogenesis is an essential biological process involved in 49 
decidualization, implantation and placentation, as well as corpus luteum (CL) formation. It is 50 
regulated by the orchestration of diverse factors such as prostaglandins (PGs) and growth factors 51 
(Fraser and Wulff, 2003; Reynolds et al., 2000; Sherer and Abulafia, 2001). Among these, 52 
vascular endothelial growth factor (VEGF) is one of the most potent angiogenic agents (Ferrara 53 
and Davis-Smyth, 1997). By acting through its two tyrosine kinase receptors, VEGFR1 (FLT1) 54 
and VEGFR2 (FLK1/KDR), VEGF modulates migration and proliferation of endothelial cells 55 
and also induces vascular permeability (Cebe-Suarez et al., 2006; Stuttfeld and Ballmer-Hofer, 56 
2009).  57 
The luteal expression and/or tissue concentration of VEGF is tightly correlated with development 58 
of the CL as shown, e.g., in primates, including humans, and cattle (Berisha et al., 2000; 59 
Ravindranath et al., 1992; Yamamoto et al., 1997). Its highest levels in growing CL correspond to 60 
the high rate of proliferation and vascularization. As clearly shown in rats and mice, interfering 61 
with the biological activity of VEGF at the level of its receptors, either VEGFR1 or VEGFR2, 62 
results in impaired formation and function of the CL by preventing angiogenesis (Ferrara, 1998; 63 
Zimmermann et al., 2001). Interestingly, however, no effects on preexisting vasculature were 64 
seen, indicating the importance of the VEGF system primarily for neo-angiogenesis (Beck and 65 
D'Amore, 1997). Furthermore, by interacting with angiopoietins, e.g., Ang1, VEGF supports 66 
integrity of blood vessels and maintains their stability (Hanahan, 1997; Hazzard and Stouffer, 67 
2000). Being itself a luteotropic factor, VEGF responds positively to LH in luteinizing granulosa 68 
cells and the developing CL, and its expression is also triggered by hypoxia (Christenson and 69 
Stouffer, 1997; Nishimura, 2010).  70 
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Less information is available concerning the expression and function of the VEGF system in the 71 
canine CL. Most of the knowledge relates to non-pregnant cyclic animals. Thus, VEGFA 72 
expression is increased during the early luteal phase, and decreases by mid-diestrus (Mariani et 73 
al., 2006). The decreased proliferative activity observed during the second half of diestrus is 74 
associated with reduced density of the vascular network, as concluded from the lower expression 75 
of endothelial cell-bound expression of endoglin (Hoffmann et al., 2004a; Papa and Hoffmann, 76 
2011). The decreased vascularization rate does not change significantly afterwards, until the end 77 
of the luteal life span (Hoffmann et al., 2004a), indicating that the diminished blood supply is not 78 
the major factor responsible for the slowly progressing luteal regression in non-pregnant dogs 79 
(Hoffmann et al., 2004b). In accordance with this, only recently unaltered levels of luteal 80 
transcripts encoding for the VEGF system were shown during normal and induced prepartum 81 
luteolysis/abortion (Kowalewski, 2014). The initially increased expression of vasculogenic 82 
factors is accompanied by elevated luteal expression of transcripts encoding for hypoxia-83 
inducible factor 1α (HIF1α) and fibroblast growth factor 2 (FGF2) in the early CL from non-84 
pregnant bitches (Papa et al., 2014).   85 
In the uterus, proper endometrial angiogenesis and vascular permeability are important for the 86 
successful onset of pregnancy (Sherer and Abulafia, 2001). VEGF is involved in these processes 87 
by coordinating the biochemical and functional changes associated with estrogen-dependent 88 
uterine edema, vascular permeability and remodeling (Cullinan-Bove and Koos, 1993; Rockwell 89 
et al., 2002; Shifren et al., 1996). High levels of uterine VEGF during early peri-implantation 90 
stages of pregnancy were found in several species, e.g., rabbit, hamster, rat, mouse and human 91 
(Das et al., 1997; Douglas et al., 2009; Rabbani and Rogers, 2001; Sugino et al., 2002; Yi et al., 92 
1999). Similarly, in the dog, increased uterine levels of transcripts encoding for VEGFA and its 93 
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receptors were found in response to free-floating, pre-implantation embryos (Bukowska et al., 94 
2011; Schafer-Somi et al., 2013). The localization and spatio-temporal expression of these factors 95 
within the canine uterus and placenta, however, have not yet been established. Blockage of 96 
VEGF in rats resulted in markedly decreased endometrial estrogen-induced microvascular 97 
permeability (Rockwell et al., 2002). Following implantation, an inadequate vascular supply may 98 
result in preeclampsia, fetal growth restriction or death (Barut et al., 2010; Cerdeira and 99 
Karumanchi, 2012; Jarvenpaa et al., 2007), and VEGF is among the most important factors 100 
involved in regulating placental angiogenesis (Reynolds and Redmer, 2001). Accordingly, in 101 
mice, knockout of either of the VEGF receptors, i.e., VEGFR1 and/or VEGFR2, results in 102 
multiple vascular malformations and consequently in embryonic lethality (Fong et al., 1995; 103 
Shalaby et al., 1995). Across species, e.g, in humans, sheep and pigs, the placental localization of 104 
VEGF is targeted to fetal trophoblast cells, showing a pregnancy stage-dependent expression 105 
pattern (Bogic et al., 2001; Demir et al., 2004; Kimberly, 2001; Winther et al., 1999).  106 
Taking into consideration the essential role of the VEGF system during the establishment and 107 
maintenance of pregnancy, this study for the first time thoroughly describes the expression and 108 
localization patterns of VEGFA, VEGFR1 and VEGFR2 in canine CL of pregnancy, as well as in 109 
utero-placental compartments collected from dogs at selected stages throughout pregnancy. 110 
Additionally, in order to investigate possible functional interplay between the VEGF system and 111 
progesterone receptor (PGR) signaling at the utero-placental level, the expression of target genes 112 
was assessed during antigestagen-induced abortion in mid-pregnant dogs.  113 
 114 
 115 
 116 
 117 
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2 Materials and Methods 118 
2.1 Tissue collection and preservation 119 
Tissue material utilized for the present study was collected by ovariohysterectomy (OHE) from 120 
healthy, mixed breed dogs at selected time points during pregnancy. The day of mating was 121 
designated as day 0 of gestation for all bitches and was 2-3 days after ovulation. The time of 122 
ovulation was detected by measuring plasma progesterone levels (>5 ng/ml in peripheral blood) 123 
at 2-3 day intervals and by vaginal cytology. The tissue samples were classified as: pre-124 
implantation (days 8-12, n=5), post-implantation (days 18-25, n=5), mid-gestation (days 35-40, 125 
n=5) and prepartum luteolysis (n=3). The pre-implantation stage of pregnancy was detected by 126 
uterine flushing and recovery of pre-implantation, free-floating embryos under a 127 
stereomicroscope. According to the descriptions by Amoroso (Amoroso, 1952) and Kehrer 128 
(Kehrer, 1973), during the post-implantation stage of canine pregnancy the utero-placental 129 
compartments are being formed, whereas at mid-gestation fully developed utero-placental 130 
compartments are observed. The prepartum luteolysis was ascertained by regular measurements 131 
of circulating P4 at 6h intervals from day 58 of gestation onwards, until a marked decrease of P4 132 
was observed in three consecutive measurements, eventually reaching levels below 3ng/ml, when 133 
OHE was performed. In addition, abortions were induced by administering Aglepristone 134 
(Alizine®, Virbac, Bad Oldesloe, Germany; 10mg/Kg bw, 2x/24 h apart) to mid-pregnant bitches 135 
(days 40-45 of pregnancy, n=10). Tissue samples were collected either 24h (n=5) or 72h (n=5) 136 
after the second treatment. All experimental procedures were performed according to the 137 
guidelines of animal welfare legislation and approved by the respective authorities of Justus-138 
Liebig University in Giessen, Germany (permit no. II 25.3-19c20-15c GI 18/14 and VIG3-19c-139 
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20/15c GI 18,14), and the ethics committee University of Ankara (permit no. Ankara 2006/06), 140 
Ankara, Turkey. 141 
The tissue samples collected comprised: Corpora lutea (CL) and uterine samples (from the pre-142 
implantation stage of pregnancy), or utero-placental compartments (ut-pl), representing the full 143 
thickness, middle part of the girdle, avoiding the marginal hematoma when derived from later 144 
stages of pregnancy following implantation and/or following Aglepristone treatment. 145 
Immediately after sampling and removal of excess connective tissue, samples were washed with 146 
phosphate-buffered saline (PBS) and processed as described before (Gram et al., 2013; 147 
Kowalewski et al., 2010; Kowalewski et al., 2011). Briefly: for immunohistochemistry (IHC), 148 
tissues were fixed with 10% neutral PBS-buffered formalin for 24h at +4oC, followed by washing 149 
in PBS for one week and embedded in paraffin wax; for total RNA isolation, samples were 150 
incubated in RNAlater® (Ambion Biotechnology GmbH, Wiesbaden, Germany) for 24h at +4°C 151 
and then stored at -80°C until analysis. 152 
 153 
2.2 Immunohistochemistry 154 
Immunohistochemical staining was performed using our previously described standard 155 
immunoperoxidase method (Kowalewski et al., 2006a; Kowalewski et al., 2006b). Briefly, 156 
formalin-fixed paraffin-embedded tissue sections (2-3µm thick) were placed on Super Frost® 157 
microscope slides (Menzel-Glaeser, Braunschweig, Germany); xylene was used for 158 
deparaffinization, then a graded ethanol series was applied for rehydration. After subsequent 159 
washing under tap water, epitope retrieval was performed in a microwave oven at 560 W for 15 160 
min in 10mM citrate buffer pH 6.0. For VEGFA and VEGFR1 localization in luteal samples, 161 
enzymatic digestion was performed with 0.25% pepsin (Sigma-Aldrich Chemie GmbH, Buchs, 162 
Switzerland) in 10mM HCl for 10 min at 37°C, instead of heat-induced antigen retrieval. 163 
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Endogenous peroxidase activity blocking was done by treating slides with 0.3% hydrogen 164 
peroxide in methanol. In order to reduce background staining, sections were incubated with either 165 
10% normal goat serum or 10% normal horse serum, depending on the source species of the 166 
secondary antibody. They were then incubated overnight at +4°C with mouse monoclonal anti-167 
VEGF (ab68334; for ut-pl tissue sections diluted 1:100, for luteal samples 1:300) purchased from 168 
Abcam, Cambridge, UK. Rabbit affinity-purified polyclonal anti-VEGFR1/Flt-1 (sc-316; for ut-169 
pl tissue sections diluted 1:300, for luteal samples 1:350) was purchased from Santa Cruz 170 
Biotechnology Inc., CA, USA, and rabbit monoclonal anti-VEGFR2/KDR/Flk-1 (2479S; for ut-171 
pl tissue sections the dilution was 1:50, for luteal samples 1:300) from Cell Signaling Technology 172 
Inc., Danvers, MA, USA. Negative controls consisted of samples omitting the primary antibody, 173 
and non-immunized IgG of the same species instead of primary antibody used at the same 174 
dilution and protein concentration as the primary antibody (the so-called isotype control). 175 
This was followed by incubation with biotin-labeled secondary antibody incubation at a 1:100 176 
dilution. The following secondary antibodies were used for 30 min: biotinylated goat anti-rabbit 177 
IgG BA-1000 and horse anti-mouse IgG BA-2000 (both from Vector Laboratories Inc., 178 
Burlingame, CA, USA). For amplification of signals, the streptavidin-peroxidase Vectastain ABC 179 
kit (Vector Laboratories, Inc.) was added to sections for 30 min, and finally they were treated 180 
with the Liquid DAB+ substrate kit (Dako Schweiz AG, Baar, Switzerland) to visualize peroxide 181 
activity. Slides were counterstained with hematoxylin, dehydrated in a graded ethanol series, 182 
equilibrated in xylene, and mounted in Histokit (Assistant, Osterode, Germany).  183 
 184 
2.3 Total RNA isolation and Real Time (TaqMan) PCR  185 
Total RNA was extracted from tissue samples with TRIzol® reagent (Invitrogen, Carlsbad, CA, 186 
USA) according to the manufacturer’s instructions. Concentrations of RNA were examined with 187 
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a NanoDrop 2000C® spectrophotometer (Thermo Fisher Scientific AG, Reinach, Switzerland). 188 
Afterwards, samples were DNAse-treated with RQ1 RNase-free DNase (Promega, Dübendorf, 189 
Switzerland) and reverse transcribed (RT reaction) following our previously published protocol 190 
and utilizing random hexamers as primers and other reagents from Applied Biosystems by 191 
Thermo Fisher Scientific, Foster City, CA, USA (Kowalewski et al., 2011; Kowalewski et al., 192 
2006b). Semi-quantitative real time (TaqMan) PCR reaction was performed in an automated 193 
fluorometer (ABI PRISM 7500 Sequence Detection System from Applied Biosystems by Thermo 194 
Fisher Scientific). The primers and probes used in the PCR reaction were designed using Primer 195 
Express software version 2.0 (Applied Biosystems by Thermo Fisher Scientific) and were 196 
purchased from Microsynth, Balgach, Switzerland. Selected amplicons of each gene were sent for 197 
commercial sequencing (Microsynth). The list of primers, 6-carboxyfluorescein (6-FAM) and 6-198 
carboxytetramethylrhodamine (TAMRA)-labelled TaqMan probes, and the length of PCR 199 
products are presented in Table 1. Autoclaved water and the so-called RT-minus controls 200 
(samples that were not reverse-transcribed) served as negative controls. Each reaction mixture 201 
comprised: 200nM TaqMan Probe, 300 nM of each primer, 12.5 µl Fast Start Universal Probe 202 
Master (ROX)® (Roche Diagnostics, Mannheim, Germany) and 5µl cDNA corresponding to 203 
100ng total RNA per sample. The amplification conditions were as follows: denaturation at 95°C 204 
for 10 min, 40 cycles at 95°C for 15 sec and 1 cycle at 60°C for 60 sec. The efficiency of each 205 
target gene was calculated using the CT slope method, ensuring approximately 100% reaction 206 
efficiency, and quantification was performed using a comparative CT method (ΔΔCT method) 207 
according to the manufacturer’s protocols for the ABI PRISM® 7500 Sequence Detection 208 
System (Applied Biosystems) and as described previously (Kowalewski et al., 2011; Kowalewski 209 
et al., 2006b).  The sample with the lowest concentration of the target gene served as the 210 
  
10 
10 
calibrator in the ΔΔCT method. Three reference genes were used for normalizing the results: 211 
GAPDH, 18SrRNA (Table 1), and cyclophilin. A commercially available gene-specific TaqMan® 212 
system of canine-specific cyclophilin A was purchased from Applied Biosystems by Thermo 213 
Fisher Scientific (Prod. No. Cf03986523_gH). 214 
Due to the uneven distribution of data, logarithmic transformation was performed for 215 
normalization of the data and the geometric means (Xg) ±  deviation factors were calculated for 216 
the analysis of target gene expression. The effects of the observational group on target gene 217 
mRNA levels were assessed by applying a parametric one-way analysis of variance (ANOVA). 218 
In cases of P<0.05, multiple comparisons tests were applied: the Tukey-Kramer multiple 219 
comparisons test in experiments showing temporal changes in gene expression during the course 220 
of pregnancy, and Dunnett's multiple comparisons test in experiments showing the expression of 221 
target genes after Aglepristone-induced luteolysis. In the latter experiments, the results present 222 
the n-fold change in gene expression compared to its mRNA-levels in ut-pl collected at mid-223 
gestation. All tests were performed using the statistical software program GraphPad 3.06 224 
(GraphPad Software, San Diego, CA, USA). 225 
 226 
3. Results 227 
3.1 Time-dependent expression of the VEGF-system in canine CL and ut-pl compartments 228 
throughout pregnancy. 229 
The expression of mRNA encoding for VEGFA and its two receptors (VEGFR1 and VEGFR2) 230 
was detectable in all tissue samples investigated. While the luteal VEGFA and VEGFR1 were 231 
significantly modulated over time (P=0.01 and P<0.001, respectively) (Fig. 1A,B), the expression 232 
of VEGFR2 did not change significantly (P=0.31) (Fig. 1C). VEGFA was elevated at the 233 
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beginning of the luteal phase with highest values noted post-implantation. This was followed by a 234 
significant decrease at mid-gestation (P<0.05) with no further changes later on, during prepartum 235 
luteolysis (Fig. 1A). A similar expression pattern was observed for luteal VEGFR1 mRNA levels, 236 
which were strongly increased post-implantation and significantly lower afterwards, at mid-term 237 
and during prepartum luteolysis (P<0.001) (Fig. 1B). 238 
The expression of all three target genes, i.e., VEGFA, VEGFR1 and VEGFR2, in ut-pl 239 
compartments was time-dependent (P=0.002, P=0.005 and P=0.001, respectively) (Fig. 2A-C). 240 
Implantation and placentation were associated with gradually increasing expression of these 241 
target genes towards mid-gestation, showing, however, large individual variations among groups 242 
and individuals. This increase was strongest for VEGFR2 mRNA, which was already 243 
significantly unpregulated in ut-pl after implantation (P<0.01), and further markedly elevated at 244 
mid-gestation (P<0.001) when compared with pre-implantation (Fig. 2C). The prepartum 245 
luteolysis was characterized by significantly decreasing levels of VEGF and VEGFR1 (P<0.001 246 
and P<0.01, respectively) (Fig. 2A,B), while VEGFR2 levels remained unaffected (Fig. 2C).  247 
 248 
3.2 The effect of antigestagen treatment on expression of the VEGF system in ut-pl 249 
compartments.  250 
The effect of applying the antigestagen Aglepristone® on expression of the VEGF system in ut-pl 251 
compartments was assessed in mid-pregnant dogs. Non-treated mid-pregnant dogs served as 252 
controls. Although displaying high individual variation, the expression of VEGFA and VEGFR2 253 
did not change significantly (P=0.75 and P=0.32, respectively) (Fig. 2D,F), while VEGFR1 254 
mRNA levels were significantly affected (P=0.006) and had already decreased 24h after the 255 
second treatment (P<0.01), remaining suppressed at 72h (P<0.01 compared with controls) (Fig. 256 
2E).  257 
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 258 
3.3 Immunohistochemical detection of the VEGF system throughout pregnancy  259 
IHC was applied for detection of VEGFA, VEGFR1 and VEGR2 expression in canine CL and ut-260 
pl compartments during pregnancy. In CL, VEGFA was localized predominantly in luteal cells, 261 
with only weak staining in non-steroidogenic luteal compartments of the CL. While characterized 262 
by high individual variations, the signals appeared stronger at post-implantation and mid-263 
gestation stages of pregnancy. Much weaker staining was observed at pre-implantation stage, and 264 
only weak or no signals could be detected during prepartum luteolysis (Fig. 3A-D). VEGFR1 265 
expression was localized to the luteal cells and tunica media of blood vessels throughout 266 
pregnancy (Fig 4A-D). At the time of prepartum luteolysis, luteal cells seemed to stain more 267 
weakly, while signals in the tunica media of vessels were still clearly visible (Fig 4D). As for 268 
VEGFR2, it was localized in luteal blood vessels with distinctly stronger signals in endothelial 269 
cells of capillaries and weaker staining in the tunica media of some larger vessels (Fig 5A-D). 270 
The staining did not vary widely throughout pregnancy. Luteal cells showed weaker or no 271 
immunoreactions for VEGFR2 from pre-implantation until prepartum luteolysis. 272 
Prior to implantation, uterine VEGFA signals were localized to the endometrial luminal surface 273 
epithelial cells, as well as in superficial and deep uterine glands and myometrium (Fig 6A,B). 274 
Deep uterine glands stained more weakly than superficial ones (Fig. 6B). Weaker stromal signals 275 
were localized predominantly in vascular endothelial cells (Fig. 6A,B). Following implantation, a 276 
similar uterine cellular localization pattern was observed for VEGFA signals in the uterine part of 277 
the ut-pl compartments (Fig 6C,D and 6F,G). However, endometrial and myometrial signals 278 
appeared to be weaker during prepartum luteolysis (Fig 6F,G). In the placental labyrinth, VEGFA 279 
signal intensities increased towards mid-gestation, resulting in strong staining in fetal trophoblast 280 
cells (predominantly cytotrophoblast), and in vascular endothelial cells both in the placenta 281 
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materna and fetalis; in contrast, only weak or no signals were observed in maternal stroma-282 
derived decidual cells (Fig 6E and 6H). Signal intensities were weaker during prepartum 283 
luteolysis (Fig 6H). 284 
The uterine expression of VEGFR1 was localized in superficial and deep uterine glands and 285 
myometrium prior to implantation (Fig 7A,B). No or negligible immunostaining was seen in 286 
luminal epithelial cells of the endometrial surface (Fig 7A). As for VEGF, some stromal signals 287 
were visible in the vascular bed. Implantation was associated with strong staining, especially in 288 
the placental parts of the ut-pl units (Fig 7C,D). The pattern of uterine VEGFR1 expression 289 
remained constant with, however, only moderate signal intensity (Fig 7C,D and Fig 7F,G ). 290 
Within the placental labyrinth, strong signals were seen in vascular endothelial cells and in 291 
cytotrophoblast cells, whereas only weak signals were localized in syncytiotrophoblast cells and 292 
maternal decidual cells (Fig 7E). During prepartum luteolysis, signals appeared weaker with, 293 
however, a localization pattern similar to that during earlier stages of pregnancy (Fig 7H). With 294 
regard to VEGFR2, its expression in the early pregnant pre-implantation uterus matched the 295 
localization pattern of VEGFA with signals localized in luminal surface epithelial cells and 296 
superficial and deep uterine glands. Stronger immunoreactions were observed in capillary 297 
pericytes, vascular endothelial cells and myometrium (Fig 8A,B). Similar endometrial and 298 
myometrial signals were found following implantation and placentation (Fig. 8C,D and 8F,G); 299 
the superficial glandular epithelial cells (part of the so-called glandular chambers), myometrium 300 
and vascular endothelial cells stained positively. Placental localization of VEGFR2 was detected 301 
in fetal trophoblast cells, which appeared to be predominantly cytotrophoblasts, and in vascular 302 
endothelial cells of the placenta materna and fetalis (Fig 8E). At prepartum luteolysis, the 303 
maternal endothelial cells especially stained strongly for VEGFR2. Only weak staining was 304 
noticed for VEGFR2 in maternal decidual cells (Fig 8E and 8H). 305 
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 306 
4. Discussion 307 
The establishment and maintenance of pregnancy strongly depend on the appropriate functioning 308 
of luteal, uterine and placental vasculogenic and angiogenic activities, and the VEGF system is a 309 
set of master regulators controlling these activities. In the present study, we investigated its 310 
spatio-temporal expression in the dog at selected time points during pregnancy, i.e., pre-311 
implantation, post-implantation, mid-gestation, and during prepartum luteolysis.  312 
The early luteal phase was characterized by elevated expression of the VEGF system in canine 313 
pregnant CL, consistent with similar findings described in other species, e.g., humans, cattle, pigs 314 
and sheep (Berisha et al., 2000; Kamat et al., 1995; Redmer et al., 1996; Yamamoto et al., 1997). 315 
The expression of transcripts encoding for VEGFA and its VEGFR1 receptor decreased by the 316 
mid-luteal phase and did not change until prepartum luteolysis. These findings are in accordance 317 
with the expression pattern of the VEGF system observed in the CL of non-pregnant cyclic dogs 318 
until late luteal regression (Mariani et al., 2006). Although individual variations were wide, the 319 
profiles of the respective protein expression of both factors, i.e., VEGFA and VEGFR1, seemed 320 
less dramatic, and showed a strong depression first appearing at prepartum luteolysis. This 321 
indicates a possible divergence between the mechanisms regulating their mRNA expression and 322 
the protein turnover rates during the regression of canine CL. Taking into account the similar P4 323 
profiles observed in dogs regardless of their reproductive status, i.e., in pregnant and non-324 
pregnant bitches, and the postulated initial transient period of gonadotropic independency, this 325 
further emphasizes the involvement of inherent regulatory mechanisms controlling canine CL 326 
function. 327 
Thus, as expected, VEGFA appears to be an essential angiogenic factor during canine CL 328 
formation. Furthermore, a functional interplay between the different cellular components in the 329 
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canine CL is strongly implied from the distribution pattern of the VEGF system within the CL. 330 
Thus, whereas in our study, VEGFA was expressed virtually exclusively in the luteal cells, its 331 
receptor VEGFR1 was localized at both locations, i.e., in steroidogenic cells and in luteal blood 332 
vessels. Moreover, VEGFR2 was co-localized with VEGFR1 in the luteal vascular components. 333 
This, indeed, strongly suggests both autocrine and paracrine functions of VEGFA and its 334 
receptors within an autoregulatory feedback loop in the canine CL. As for the possible regulatory 335 
factors modulating VEGFA expression, the hypoxia-sensitive HIF1α might be involved, as its 336 
expression is clearly detectable during the developmental period of canine CL (Papa et al., 2013). 337 
Moreover, PGE2 was shown to be a positive regulator of VEGF expression in swine luteal cells 338 
in vitro (Kowalczyk et al., 2008). Similarly, in rodents, blocking cyclooxygenase 2 339 
(COX2/PTGS2) in the newly formed CL, using the selective COX2 blocker NS-398, decreased 340 
not only the steroidogenic luteal capacity and, thereby, serum levels of P4, but also the density of 341 
luteal capillary vessels (Sakurai et al., 2005). In line with this, PGE2 is also an important 342 
regulator of CL function in dogs during its early development (Kowalewski et al., 2013; 343 
Kowalewski et al., 2015). This was clearly shown recently by applying the selective COX2 344 
blocker firocoxib to non-pregnant dogs during early diestrus, which resulted in strong 345 
suppression of intraluteal PGE2 synthesis and decreased expression of steroidogenic acute 346 
regulatory (STAR) protein (Kowalewski et al., 2015). The possible interplay between these two 347 
functional systems, i.e., PGs and VEGF system, in regulating STAR expression and luteal P4 348 
output remains to be elucidated in the dog. This is particularly interesting since the steroidogenic 349 
potential of VEGF has been implicated also in the cow, where antibody-mediated blocking of 350 
VEGF function resulted in suppressed luteal STAR mRNA expression and significantly reduced 351 
steroidogenic output (Yamashita et al., 2008). 352 
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As for the ut-pl compartments, the expression of VEGFA and its receptors increased following 353 
implantation, appearing to be associated with placental development, as indicated by the strong 354 
expression of all factors in the fetal parts of the placenta.  355 
At the pre-implantation stage, VEGFA was localized in capillaries and epithelial uterine 356 
components, implying a role of VEGFA in establishing the uterine edema and vascular 357 
permeabilization needed for embryo attachment and implantation as described in other species 358 
(Ancelin et al., 2002; Halder et al., 2000; Rockwell et al., 2002). Accordingly, studies conducted 359 
in human and rat uterus showed that VEGF expression is induced by P4 and estrogens (Ancelin 360 
et al., 2002; Cullinan-Bove and Koos, 1993; Hyder et al., 2000). This might be also true for dogs, 361 
in which uterine P4- and estrogen- receptors (PGR, ERα and ERβ) were colocalized with 362 
VEGFA expression during the pre-implantation period (Kautz et al., 2014). Additional studies in 363 
rodents established the interrelationship between VEGF activity and estrogen-induced uterine 364 
decidualization and implantation (Rockwell et al., 2002). Moreover, VEGFR2-mediated 365 
pathways were shown to be involved in regulation of cell differentiation during establishment of 366 
pregnancy in mice (Douglas et al., 2009). Also in the dog, as presented herein, VEGFR2 367 
expression was stronger than VEGFR1 in uterine and placental vascular beds, suggesting the 368 
important role of this receptor in local VEGFA-dependent angiogenic effects.  369 
Following placentation, endometrial signals for VEGF and its receptors were similar to those 370 
observed in the pre-implantation uterus. However, strong placental signals were localized in fetal 371 
trophoblast cells, suggesting that the VEGF system might play an autocrine and/or paracrine role 372 
in placental angiogenesis, and in maintaining changes in utero-placental vascular permeability, 373 
and thereby, in fetal and placental development. Our findings concerning the distribution pattern 374 
of VEGF system in trophoblast cells are in agreement with similar studies performed in other 375 
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species, e.g., human, sheep or rat (Ahmed et al., 1995; Bogic et al., 2001; Demir et al., 2004; 376 
Watanabe, 1998). Whereas during prepartum luteolysis the expression of VEGFR2 remained 377 
unaffected, the VEGFA and VEGFR1 were markedly suppressed. In the dog, interfering with P4 378 
function by blocking its binding to PGR triggers the luteolytic cascade, resulting in the prepartum 379 
PGF2α increase (Kowalewski et al., 2010). Considering the placenta, this increase must originate 380 
in trophoblast cells where COX2 is localized (Kowalewski et al., 2010). Recently, the potential of 381 
canine placental and uterine homogenates to convert PGE2 to PGF2α was shown (Gram et al., 382 
2014). In addition, the PGE2-generating enzyme, PTGES, was localized in the fetal trophoblast 383 
and responded positively to the suppression of PGR function (Gram et al., 2014; Kowalewski et 384 
al., 2010). In the present study, both VEGFA and VEGFR2 exhibited large individual variations 385 
upon treatment with the antigestagen Aglepristone®, contrasting with the strongly suppressed 386 
expression of VEGFR1. The latter in particular can be seen as a sign of a functional change 387 
within the trophoblast towards prepartum PG synthesis and induction of the luteolytic cascade. 388 
Suppression of the VEGF system function during both normal and induced parturition/abortion 389 
might be involved in facilitating placental detachment. 390 
In conclusion, the VEGF system is actively modulated in canine CL and ut-pl compartments 391 
throughout gestation. Whereas, at least at the mRNA level, its expression is strongly diminished 392 
in mature, mid-term CL exhibiting a fully developed vascular bed, the strong placental 393 
expression of VEGFA and both receptors suggests their involvement not only in placental 394 
angiogenesis and vasculogenesis but also during maintenance of placental function, possibly by 395 
supporting trophoblast differentiation and/or migration. 396 
  397 
 398 
  
18 
18 
Acknowledgements: 399 
Authors are grateful to Prof. Dr. Selim Aslan, Near East University, Cyprus (formerly of the 400 
University of Ankara, Turkey), and his team for provision of the tissue material, and to Dr. Barry 401 
Bavister for careful editing of the manuscript. The technical expertise and contributions of 402 
Elisabeth Högger and Stefanie Ihle are greatly appreciated.  403 
 404 
Grant support: Swiss National Science Foundation (SNSF) research grant number 405 
31003A_160251 to MPK. 406 
 407 
 408 
Conflict of interest: The authors declare that there is no conflict of interest. All authors read and 409 
approved the final version of the manuscript. 410 
 411 
 412 
413 
  
19 
19 
References: 414 
Ahmed, A., Li, X.F., Dunk, C., Whittle, M.J., Rushton, D.I., Rollason, T., 1995. Colocalisation of 415 
vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors 12, 416 
235-243. 417 
Amoroso, E.C., 1952. Placentation. In: Parkers AS (ed.) Marshall`s physiology of reproduction. 418 
Longmans Green, London. 127-316. 419 
Ancelin, M., Buteau-Lozano, H., Meduri, G., Osborne-Pellegrin, M., Sordello, S., Plouet, J., 420 
Perrot-Applanat, M., 2002. A dynamic shift of VEGF isoforms with a transient and selective 421 
progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability 422 
in human uterus. Proc Natl Acad Sci U S A 99, 6023-6028. 423 
Barut, F., Barut, A., Gun, B.D., Kandemir, N.O., Harma, M.I., Harma, M., Aktunc, E., Ozdamar, 424 
S.O., 2010. Intrauterine growth restriction and placental angiogenesis. Diagn Pathol 5, 24. 425 
Beck, L., Jr., D'Amore, P.A., 1997. Vascular development: cellular and molecular regulation. 426 
Faseb J 11, 365-373. 427 
Berisha, B., Schams, D., Kosmann, M., Amselgruber, W., Einspanier, R., 2000. Expression and 428 
tissue concentration of vascular endothelial growth factor, its receptors, and localization in the 429 
bovine corpus luteum during estrous cycle and pregnancy. Biol Reprod 63, 1106-1114. 430 
Bogic, L.V., Brace, R.A., Cheung, C.Y., 2001. Developmental expression of vascular endothelial 431 
growth factor (VEGF) receptors and VEGF binding in ovine placenta and fetal membranes. 432 
Placenta 22, 265-275. 433 
Bukowska, D., Kempisty, B., Jackowska, M., Wozna, M., Antosik, P., Piotrowska, H., 434 
Jaskowski, J.M., 2011. Analysis of integrins and vascular endothelial growth factor isoforms 435 
mRNA expression in the canine uterus during perimplantation period. Pol J Vet Sci 14, 253-258. 436 
Cebe-Suarez, S., Zehnder-Fjallman, A., Ballmer-Hofer, K., 2006. The role of VEGF receptors in 437 
angiogenesis; complex partnerships. Cell Mol Life Sci 63, 601-615. 438 
Cerdeira, A.S., Karumanchi, S.A., 2012. Angiogenic factors in preeclampsia and related 439 
disorders. Cold Spring Harb Perspect Med 2(11). 440 
Christenson, L.K., Stouffer, R.L., 1997. Follicle-stimulating hormone and luteinizing 441 
hormone/chorionic gonadotropin stimulation of vascular endothelial growth factor production by 442 
macaque granulosa cells from pre- and periovulatory follicles. J Clin Endocrinol Metab 82, 2135-443 
2142. 444 
Cullinan-Bove, K., Koos, R.D., 1993. Vascular endothelial growth factor/vascular permeability 445 
factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced 446 
increases in uterine capillary permeability and growth. Endocrinology 133, 829-837. 447 
Das, S.K., Chakraborty, I., Wang, J., Dey, S.K., Hoffman, L.H., 1997. Expression of vascular 448 
endothelial growth factor (VEGF) and VEGF-receptor messenger ribonucleic acids in the peri-449 
implantation rabbit uterus. Biol Reprod 56, 1390-1399. 450 
Demir, R., Kayisli, U.A., Seval, Y., Celik-Ozenci, C., Korgun, E.T., Demir-Weusten, A.Y., 451 
Huppertz, B., 2004. Sequential expression of VEGF and its receptors in human placental villi 452 
during very early pregnancy: differences between placental vasculogenesis and angiogenesis. 453 
Placenta 25, 560-572. 454 
Douglas, N.C., Tang, H., Gomez, R., Pytowski, B., Hicklin, D.J., Sauer, C.M., Kitajewski, J., 455 
Sauer, M.V., Zimmermann, R.C., 2009. Vascular endothelial growth factor receptor 2 (VEGFR-456 
2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse. 457 
Endocrinology 150, 3845-3854. 458 
  
20 
20 
Ferrara, N., Davis-Smyth, T., 1997. The biology of vascular endothelial growth factor. Endocr 459 
Rev 18, 4-25. 460 
Ferrara, N.C., H. Davis-Symth,T. Gerberer,H. Nguyen,T.N. Chisholm,V. Hillan,K. Schwall,R., 461 
1998. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature 4, 462 
336-340. 463 
Fong, G.H., Rossant, J., Gertsenstein, M., Breitman, M.L., 1995. Role of the Flt-1 receptor 464 
tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70. 465 
Fraser, H.M., Wulff, C., 2003. Angiogenesis in the corpus luteum. Reprod Biol Endocrinol 1, 88. 466 
Gram, A., Buchler, U., Boos, A., Hoffmann, B., Kowalewski, M.P., 2013. Biosynthesis and 467 
degradation of canine placental prostaglandins: prepartum changes in expression and function of 468 
prostaglandin F2α-synthase (PGFS, AKR1C3) and 15-hydroxyprostaglandin dehydrogenase 469 
(HPGD). Biol Reprod 89(1):2. 470 
Gram, A., Fox, B., Buchler, U., Boos, A., Hoffmann, B., Kowalewski, M.P., 2014. Canine 471 
placental prostaglandin E2 synthase: expression, localization, and biological functions in 472 
providing substrates for prepartum PGF2alpha synthesis. Biol Reprod 91(6):154. 473 
Halder, J.B., Zhao, X., Soker, S., Paria, B.C., Klagsbrun, M., Das, S.K., Dey, S.K., 2000. 474 
Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropilin-1 in the 475 
mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during 476 
implantation. Genesis 26, 213-224. 477 
Hanahan, D., 1997. Signaling vascular morphogenesis and maintenance. Science 277, 48-50. 478 
Hazzard, T.M., Stouffer, R.L., 2000. Angiogenesis in ovarian follicular and luteal development. 479 
Baillieres Best Pract Res Clin Obstet Gynaecol 14, 883-900. 480 
Hoffmann, B., Busges, F., Baumgartner, W., 2004a. Immunohistochemical detection of CD4-, 481 
CD8- and MHC II-expressing immune cells and endoglin in the canine corpus luteum at different 482 
stages of dioestrus. Reprod Domest Anim 39, 391-395. 483 
Hoffmann, B., Busges, F., Engel, E., Kowalewski, M.P., Papa, P., 2004b. Regulation of corpus 484 
luteum-function in the bitch. Reprod Domest Anim 39, 232-240. 485 
Hyder, S.M., Huang, J.C., Nawaz, Z., Boettger-Tong, H., Makela, S., Chiappetta, C., Stancel, 486 
G.M., 2000. Regulation of vascular endothelial growth factor expression by estrogens and 487 
progestins. Environ Health Perspect 108 Suppl 5, 785-790. 488 
Jarvenpaa, J., Vuoristo, J.T., Savolainen, E.R., Ukkola, O., Vaskivuo, T., Ryynanen, M., 2007. 489 
Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with 490 
intrauterine growth restriction. Gynecol Endocrinol 23, 351-355. 491 
Kamat, B.R., Brown, L.F., Manseau, E.J., Senger, D.R., Dvorak, H.F., 1995. Expression of 492 
vascular permeability factor/vascular endothelial growth factor by human granulosa and theca 493 
lutein cells. Role in corpus luteum development. Am J Pathol 146, 157-165. 494 
Kautz, E., Gram, A., Aslan, S., Ay, S.S., Selcuk, M., Kanca, H., Koldas, E., Akal, E., Karakas, 495 
K., Findik, M., Boos, A., Kowalewski, M.P., 2014. Expression of genes involved in the embryo-496 
maternal interaction in the early pregnant canine uterus. Reproduction, 703-717. 497 
Kehrer, A., 1973. [Chorionic development and structure of the placenta zonaria in the cat, dog 498 
and fox (author's transl)]. Z Anat Entwicklungsgesch 143, 25-42. 499 
Kimberly, A.V.M., E.W. Stephan,P.F., 2001. Relationship Between Placental Vascular 500 
Endothelial Growth Factor Expression and Placental/Endometrial Vascularity in the Pig. Biol 501 
Reprod, 1821-1825. 502 
Kowalczyk, A.E., Kaczmarek, M.M., Schams, D., Ziecik, A.J., 2008. Effect of prostaglandin E2 503 
and tumor necrosis factor alpha on the VEGF-receptor system expression in cultured porcine 504 
luteal cells. Mol Reprod Dev 75, 1558-1566. 505 
  
21 
21 
Kowalewski, M.P., 2014. Luteal regression vs. prepartum luteolysis: regulatory mechanisms 506 
governing canine corpus luteum function. Reprod Biol 14, 89-102. 507 
Kowalewski, M.P., Beceriklisoy, H.B., Pfarrer, C., Aslan, S., Kindahl, H., Kucukaslan, I., 508 
Hoffmann, B., 2010. Canine placenta: a source of prepartal prostaglandins during normal and 509 
antiprogestin-induced parturition. Reproduction 139, 655-664. 510 
Kowalewski, M.P., Fox, B., Gram, A., Boos, A., Reichler, I., 2013. Prostaglandin E2 functions as 511 
a luteotrophic factor in the dog. Reproduction 145, 213-226. 512 
Kowalewski, M.P., Ihle, S., Siemieniuch, M.J., Gram, A., Boos, A., Zdunczyk, S., Fingerhut, J., 513 
Hoffmann, B., Schuler, G., Jurczak, A., Domoslawska, A., Janowski, T., 2015. Formation of the 514 
early canine CL and the role of prostaglandin E2 (PGE2) in regulation of its function: an in vivo 515 
approach. Theriogenology 83, 1038-1047. 516 
Kowalewski, M.P., Mason, J.I., Howie, A.F., Morley, S.D., Schuler, G., Hoffmann, B., 2006a. 517 
Characterization of the canine 3beta-hydroxysteroid dehydrogenase and its expression in the 518 
corpus luteum during diestrus. J Steroid Biochem Mol Biol 101, 254-262. 519 
Kowalewski, M.P., Meyer, A., Hoffmann, B., Aslan, S., Boos, A., 2011. Expression and 520 
functional implications of peroxisome proliferator-activated receptor gamma (PPARgamma) in 521 
canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced 522 
abortion. Theriogenology 75, 877-886. 523 
Kowalewski, M.P., Schuler, G., Taubert, A., Engel, E., Hoffmann, B., 2006b. Expression of 524 
cyclooxygenase 1 and 2 in the canine corpus luteum during diestrus. Theriogenology 66, 1423-525 
1430. 526 
Mariani, T.C., do Prado, C., Silva, L.G., Paarmann, F.A., Lima, M.C., Carvalho, I., Campos, 527 
D.B., Artoni, L.P., Hernandez-Blazquez, F.J., Papa, P.C., 2006. Immunohistochemical 528 
localization of VEGF and its receptors in the corpus luteum of the bitch during diestrus and 529 
anestrus. Theriogenology 66, 1715-1720. 530 
Nishimura, R.O., K., 2010. Hypoxia is Important for Establishing Vascularization During Corpus 531 
Luteum Formation in Cattle. J Reprod Dev, 110-116. 532 
Papa, P.C., Hoffmann, B., 2011. The corpus luteum of the dog: source and target of steroid 533 
hormones? Reprod Domest Anim 46, 750-756. 534 
Papa, P.C., Sousa, L.M., Silva Rdos, S., de Fatima, L.A., da Fonseca, V.U., do Amaral, V.C., 535 
Hoffmann, B., Alves-Wagner, A.B., Machado, U.F., Kowalewski, M.P., 2013. Glucose 536 
transporter 1 expression accompanies hypoxia sensing in the cyclic canine corpus luteum. 537 
Reproduction 147, 81-89. 538 
Papa, P,C., Sousa, L.M., Silva Rdos, S., de Fatima, L.A., da Fonseca, V.U., do Amaral, V.C., 539 
Hoffmann, B., Alves-Wagner, A.B., Machado, U.F., Kowalewski, M.P., 2014. Glucose 540 
transporter 1 expression accompanies hypoxia sensing in the cyclic canine corpus luteum. 541 
Reproduction 147, 81-89. 542 
Rabbani, M.L., Rogers, P.A., 2001. Role of vascular endothelial growth factor in endometrial 543 
vascular events before implantation in rats. Reproduction 122, 85-90. 544 
Ravindranath, N., Little-Ihrig, L., Phillips, H.S., Ferrara, N., Zeleznik, A.J., 1992. Vascular 545 
endothelial growth factor messenger ribonucleic acid expression in the primate ovary. 546 
Endocrinology 131, 254-260. 547 
Redmer, D.A., Dai, Y., Li, J., Charnock-Jones, D.S., Smith, S.K., Reynolds, L.P., Moor, R.M., 548 
1996. Characterization and expression of vascular endothelial growth factor (VEGF) in the ovine 549 
corpus luteum. J Reprod Fertil 108, 157-165. 550 
Reynolds, L.P., Grazul-Bilska, A.T., Redmer, D.A., 2000. Angiogenesis in the corpus luteum. 551 
Endocrine 12, 1-9. 552 
  
22 
22 
Reynolds, L.P., Redmer, D.A., 2001. Angiogenesis in the placenta. Biol Reprod 64, 1033-1040. 553 
Rockwell, L.C., Pillai, S., Olson, C.E., Koos, R.D., 2002. Inhibition of vascular endothelial 554 
growth factor/vascular permeability factor action blocks estrogen-induced uterine edema and 555 
implantation in rodents. Biol Reprod 67, 1804-1810. 556 
Sakurai, T., Tamura, K., Kogo, H., 2005. Stimulatory effects of eicosanoids on ovarian 557 
angiogenesis in early luteal phase in cyclooxygenase-2 inhibitor-treated rats. Eur J Pharmacol 558 
516, 158-164. 559 
Schafer-Somi, S., Sabitzer, S., Klein, D., Reinbacher, E., Kanca, H., Beceriklisoy, H.B., Aksoy, 560 
O.A., Kucukaslan, I., Macun, H.C., Aslan, S., 2013. Vascular endothelial (VEGF) and epithelial 561 
growth factor (EGF) as well as platelet-activating factor (PAF) and receptors are expressed in the 562 
early pregnant canine uterus. Reprod Domest Anim 48, 20-26. 563 
Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L., Schuh, 564 
A.C., 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 565 
376, 62-66. 566 
Sherer, D.M., Abulafia, O., 2001. Angiogenesis during implantation, and placental and early 567 
embryonic development. Placenta 22, 1-13. 568 
Shifren, J.L., Tseng, J.F., Zaloudek, C.J., Ryan, I.P., Meng, Y.G., Ferrara, N., Jaffe, R.B., Taylor, 569 
R.N., 1996. Ovarian steroid regulation of vascular endothelial growth factor in the human 570 
endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis 571 
of endometriosis. J Clin Endocrinol Metab 81, 3112-3118. 572 
Stuttfeld, E., Ballmer-Hofer, K., 2009. Structure and function of VEGF receptors. IUBMB Life 573 
61, 915-922. 574 
Sugino, N., Kashida, S., Karube-Harada, A., Takiguchi, S., Kato, H., 2002. Expression of 575 
vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout 576 
the menstrual cycle and in early pregnancy. Reproduction 123, 379-387. 577 
Watanabe, A.Y., T. Hoshi, K. Katoh, R. Kawaoi, A. Shibuya, M., 1998. Vascular Endothelial 578 
Growth Factor Expression in the Rat Uterus and Placenta throughout Pregnancy. Acta Histochem. 579 
Cytochem. 31, 419-426. 580 
Winther, H., Ahmed, A., Dantzer, V., 1999. Immunohistochemical localization of vascular 581 
endothelial growth factor (VEGF) and its two specific receptors, Flt-1 and KDR, in the porcine 582 
placenta and non-pregnant uterus. Placenta 20, 35-43. 583 
Yamamoto, S., Konishi, I., Tsuruta, Y., Nanbu, K., Mandai, M., Kuroda, H., Matsushita, K., 584 
Hamid, A.A., Yura, Y., Mori, T., 1997. Expression of vascular endothelial growth factor (VEGF) 585 
during folliculogenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol 11, 586 
371-381. 587 
Yamashita, H., Kamada, D., Shirasuna, K., Matsui, M., Shimizu, T., Kida, K., Berisha, B., 588 
Schams, D., Miyamoto, A., 2008. Effect of local neutralization of basic fibroblast growth factor 589 
or vascular endothelial growth factor by a specific antibody on the development of the corpus 590 
luteum in the cow. Mol Reprod Dev 75, 1449-1456. 591 
Yi, X.J., Jiang, H.Y., Lee, K.K., O, W.S., Tang, P.L., Chow, P.H., 1999. Expression of vascular 592 
endothelial growth factor (VEGF) and its receptors during embryonic implantation in the golden 593 
hamster (Mesocricetus auratus). Cell Tissue Res 296, 339-349. 594 
Zimmermann, R.C., Hartman, T., Bohlen, P., Sauer, M.V., Kitajewski, J., 2001. Preovulatory 595 
treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. 596 
Microvasc Res 62, 15-25. 597 
 598 
599 
  
23 
23 
Figure legends 600 
Figure 1: Expression of VEGFA, VEGFR1/FLT1 and VEGFR2/FLK1/KDR as determined by 601 
Real Time (TaqMan) PCR (Xg ± DF) in canine CL at selected stages of pregnancy (A-C). Bars 602 
with different letters in (A) differ at differ at P<0.05, and in (B) differ at P<0.001.  603 
 604 
Figure 2: Expression of VEGFA, VEGFR1/FLT1 and VEGFR2/FLK1/KDR as determined by 605 
Real Time (TaqMan) PCR (Xg ± DF) in canine pre-implantation pregnant uterus and in utero-606 
placental compartments (ut-pl) at selected time points of pregnancy (A-C) and during 607 
antigestagen (Aglepristone®)-induced luteolysis/abortion (D-F; compared with the mid-gestation 608 
group used as non-treated control). Bars with different letters differ: in (A) at P<0.001, in (B) and 609 
(E) at P<0.01. For (C) differences are indicated underneath the graph. 610 
 611 
Figure 3: Immunohistochemical (IHC) localization of VEGFA in the canine CL at selected time 612 
points of pregnancy, i.e., pre-implantation (A), post-implantation (B), mid-gestation (C) and at 613 
prepartum luteolysis (D). VEGFA expression is localized to the lutein cells (solid arrows in A-614 
D). There is no background staining in the isotype control (insert to D). 615 
 616 
Figure 4: Immunohistochemical (IHC) localization of VEGFR1/FLT1 in the canine pregnant CL 617 
at selected time points of pregnancy, i.e., pre-implantation (A), post-implantation (B), mid-618 
gestation (C) and prepartum luteolysis (D). VEGFR1 expression is localized to the luteal cells 619 
(open arrows in A-D) and media of the blood vessels (solid arrows in A-D). There is no 620 
background staining in the isotype control (insert to D). 621 
 622 
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Figure 5: Immunohistochemical (IHC) localization of VEGFR2/FLK1/KDR in the canine 623 
pregnant CL at selected time points of pregnancy, i.e., pre-implantation (A), post-implantation 624 
(B), mid-gestation (C) and prepartum luteolysis (D). VEGFR2 expression is predominantly 625 
localized to the capillary endothelial cells (open arrows in A-D), while weaker staining is 626 
observed in media of some larger vessels (solid arrow in C). Luteal cells stain only weakly or 627 
negatively (solid arrowheads in A-D). There is no background staining in the isotype control 628 
(insert to D). 629 
 630 
Figure 6: Immunohistochemical (IHC) localization of VEGFA in the canine pregnant uterus at 631 
selected time points during pregnancy: (A,B) pre-implantation stage, (C-E) utero-placental 632 
compartments (ut-pl) at mid-gestation, and in ut-pl at prepartum luteolysis (F-H). (A,B) Pre-633 
implantation, VEGFA is localized to the endometrial luminal (surface) epithelial cells (solid 634 
arrows in A), glandular epithelial cells of the superficial and deep uterine glands (open arrows in 635 
A and B), myometrium (open arrowheads in B) and capillary pericytes (solid arrowheads in A 636 
and B). (C-E) Following placentation (representative pictures taken during mid-gestation) within 637 
the ut-pl compartments, endometrial VEGFA expression is localized in the epithelial cells of the 638 
superficial endometrial glands (the so-called glandular chambers) (open arrows in C) and deep 639 
uterine glands (open arrows in D), media of the vessels (solid arrowhead in C) and myometrium 640 
(open arrowheads in D). At prepartum luteolysis (F-G), positive uterine signals are localized in 641 
the superficial (open arrows in F) and deep uterine glands (open arrows in G), vascular 642 
endothelial cells (solid arrowheads in G) and myometrium (open arrowheads in G). Within the 643 
placental labyrinth, signals are localized in fetal trophoblast cells (cytotrophoblast, solid 644 
arrowheads in E and H) and maternal endothelial cells (open arrows in E and H) with distinctly 645 
stronger signals observed at earlier stages of pregnancy (presented at mid-gestation, E) than 646 
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during prepartum luteolysis (H). Maternal stroma-derived decidual cells (open arrowheads in H) 647 
display only weak staining. There is no background staining in the isotype control (insert to H). 648 
 649 
Figure 7: Immunohistochemical (IHC) localization of VEGFR1/FLT1 in the canine pregnant 650 
uterus at selected time points during pregnancy: (A,B) pre-implantation stage, (C-E) utero-651 
placental compartments (ut-pl) at mid-gestation, and in ut-pl at prepartum luteolysis (F-H). (A,B) 652 
pre-implantation endometrial luminal (surface) epithelial cells stain weakly for VEGFR1 (solid 653 
arrows in A). Stronger endometrial signals are localized to the glandular epithelial cells of the 654 
superficial and deep uterine glands (open arrows in A and B), and media of the vessels (solid 655 
arrowheads in B). Myometrium stains positively (open arrowheads in B). Following implantation 656 
(presented at mid-gestation in C and D), and at prepartum-luteolysis (F, G), similar endometrial 657 
and myometrial localization patterns are observed. Signals are shown in glandular epithelial cells 658 
of the superficial glands (the so-called glandular chambers; open arrows in C and F), deep uterine 659 
glands (open arrows in D and G), and myocytes (open arrowheads in D and G). In the placental 660 
labyrinth during mid-gestation and prepartum luteolysis, cytotrophoblast cells (solid arrowheads 661 
in E and H) are stained, with distinctly stronger signals at earlier stages of pregnancy (represented 662 
at mid-gestation in E). Maternal endothelial cells are indicated with open arrows in E and H. 663 
Maternal stroma-derived decidual cells display only weak staining (open arrowheads in E and H). 664 
There is no background staining in the isotype control (insert to H). 665 
 666 
Figure 8 Immunohistochemical (IHC) localization of VEGFR2/FLK1/KDR in the canine 667 
pregnant uterus at selected time points during pregnancy: (A,B) pre-implantation stage, (C-E) 668 
utero-placental compartments (ut-pl) at mid-gestation, and in ut-pl at prepartum luteolysis (F-H). 669 
(A,B ) Pre-implantation endometrial luminal (surface) epithelial cells (solid arrows in A), 670 
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26 
capillary pericytes (solid arrowheads in A and B) and myometrial myocytes (open arrowheads in 671 
B) are stained strongly for VEGFR2. Weaker endometrial signals are localized to the glandular 672 
epithelial cells of the superficial and deep uterine glands (open arrows in A and B). Following 673 
implantation (presented at mid-gestation; C-E), strong endometrial signals are localized in the 674 
epithelium of superficial glands (the so-called glandular chambers, open arrows in C), capillary 675 
pericytes (solid arrowheads in C and D) and vascular endothelial cells (solid arrow in D). Deep 676 
uterine glands (open arrows in D) are stained weakly for VEGFR2. In myometrium, signals are 677 
localized in myocytes (open arrowheads in D). At prepartum luteolysis, similar endometrial and 678 
myometrial localization patterns are observed (F and G). Signals are localized to the glandular 679 
epithelial cells of glandular chambers (open arrows in F) and deep uterine glands (open arrows in 680 
G), capillary pericytes (solid arrowheads in F) and myocytes (open arrowheads in G). In the 681 
placental labyrinth (presented at mid-gestation) trophoblast cells (cytotrophoblast, solid 682 
arrowheads in E), capillary pericytes (solid arrows in E), and maternal endothelial cells (open 683 
arrow in E), are predominantly stained. During prepartum luteolysis, strong staining is localized 684 
in maternal endothelial cells (open arrow in H). Positively stained cytotrophoblast is indicated 685 
with solid arrowheads in H. Only weak staining is observed in maternal decidual cells throughout 686 
gestation (open arrowheads in H) and syncytiotrophoblast (solid arrows in H). There is no 687 
background staining in the isotype control (insert to H). 688 
 689 
Table1 690 
List of primers and TaqMan Probes used for the semi-quantitative RT-PCR 691 









